Today’s Rating On Watch: JP Morgan Cazenove Reaffirms Shire PLC (LON:SHP) as “Overweight”

November 28, 2016 - By Nellie Frank

Shire PLC (LON:SHP) Rating

Shire PLC (LON:SHP) stock “Overweight” was restate by Analysts at JP Morgan Cazenove in a research note sent to investors and clients on Monday morning.

Shire PLC (LON:SHP) Ratings Coverage

Out of 24 analysts covering Shire PLC (LON:SHP), 21 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 88% are positive. GBX 6900 is the highest target while GBX 234 is the lowest. The GBX 5404 average target is 15.17% above today’s (GBX 4692) stock price. Shire PLC has been the topic of 231 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The stock of Shire PLC (LON:SHP) has “Outperform” rating given on Tuesday, April 26 by BNP Paribas. The stock has “Buy” rating given by Berenberg on Friday, January 8. BNP Paribas downgraded the shares of SHP in a report on Thursday, August 6 to “Neutral” rating. The stock has “Outperform” rating given by BNP Paribas on Monday, February 22. The firm has “Outperform” rating given on Monday, November 2 by Bernstein. The company was maintained on Sunday, October 4 by Bernstein. Shore Capital maintained the shares of SHP in a report on Friday, August 12 with “Buy” rating. On Wednesday, August 3 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock has “Buy” rating given by Deutsche Bank on Monday, November 14. The rating was maintained by Liberum Capital with “Buy” on Tuesday, July 12.

About 301,251 shares traded hands. Shire PLC (LON:SHP) has risen 11.99% since April 28, 2016 and is uptrending. It has outperformed by 5.98% the S&P500.

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The company has a market cap of 42.30 billion GBP. The Firm operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It has a 66.08 P/E ratio.

More recent Shire PLC (LON:SHP) news were published by: Streetinsider.com which released: “Shire plc (SHPG) Misses Q3 EPS by 4c” on November 01, 2016. Also Seekingalpha.com published the news titled: “Shire Plc (SHPG) Q3 2016 Results – Earnings Call Transcript” on November 01, 2016. Bostonglobe.com‘s news article titled: “Shire to lease Genzyme building as part of Kendall Square expansion” with publication date: November 22, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>